ANDA 76161, held by Strides Pharma Intl. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 76161 (Doxazosin Mesylate), held by Strides Pharma Intl, was first approved by FDA on Jun 10, 2004, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 10, 2004 | Original application | Approved | None posted |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Oct 27, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 6, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 6, 2017 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 10, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters